{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T14:18:37Z","timestamp":1697465917583},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[1999,12,1]],"date-time":"1999-12-01T00:00:00Z","timestamp":944006400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Hypertens Rep"],"published-print":{"date-parts":[[1999,12]]},"DOI":"10.1007\/s11906-996-0024-9","type":"journal-article","created":{"date-parts":[[2007,5,25]],"date-time":"2007-05-25T20:17:21Z","timestamp":1180124241000},"page":"512-520","source":"Crossref","is-referenced-by-count":7,"title":["Controversies surrounding the treatment of the hypertensive patient with diabetes"],"prefix":"10.1007","volume":"1","author":[{"given":"L. Michael","family":"Prisant","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita J.","family":"Louard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"24_CR1","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1136\/bmj.316.7134.823","volume":"316","author":"RC Turner","year":"1998","unstructured":"Turner RC, Millns H, Neil HA, et al.: Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998, 316:823\u2013828.","journal-title":"BMJ"},{"key":"24_CR2","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.2337\/diacare.22.8.1354","volume":"22","author":"American Diabetes Association","year":"1999","unstructured":"American Diabetes Association: Standards of medical care for patients with diabetes mellitus. Diabetes Care 1999, 22 S32-S41.","journal-title":"Diabetes Care"},{"key":"24_CR3","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.2337\/diacare.22.1.56","volume":"22","author":"American Diabetes Association","year":"1999","unstructured":"American Diabetes Association: Management of dyslipidemia in adults with diabetes. Diabetes Care 1999, 22:S56-S59.","journal-title":"Diabetes Care"},{"key":"24_CR4","doi-asserted-by":"crossref","unstructured":"The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997, 157:2413\u20132446.","DOI":"10.1001\/archinte.157.21.2413"},{"key":"24_CR5","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJM199807233390404","volume":"339","author":"SM Haffner","year":"1998","unstructured":"Haffner SM, Lehto S, Ronnemaa T, et al.: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998, 339:229\u2013234. Diabetes mellitus carries the same risk as a previous myocardial infarction","journal-title":"N Engl J Med"},{"key":"24_CR6","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2337\/diacare.21.1.193","volume":"21","author":"M Pahor","year":"1998","unstructured":"Pahor M, Kritchevsky SB, Zuccala G, Guralnik JM: Diabetes and risk of adverse events with calcium antagonists. Diabetes Care 1998, 21:193\u2013194.","journal-title":"Diabetes Care"},{"issue":"suppl 4","key":"24_CR7","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2337\/diacare.14.4.39","volume":"14","author":"C Berne","year":"1991","unstructured":"Berne C, Pollare T, Lithell H: Effects of antihypertensive treatment on insulin sensitivity with special reference to ACE inhibitors. Diabetes Care 1991, 14(suppl 4):39\u201347.","journal-title":"Diabetes Care"},{"key":"24_CR8","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1093\/ajh\/2.6.419","volume":"2","author":"AL Swislocki","year":"1989","unstructured":"Swislocki AL, Hoffman BB, Reaven GM: Insulin resistance, glucose intolerance and hyperinsulinemia in patients with hypertension. Am J Hypertens 1989, 2 (6 pt 1):419\u2013423.","journal-title":"Am J Hypertens"},{"key":"24_CR9","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/ajh\/5.10.775","volume":"5","author":"LM Prisant","year":"1992","unstructured":"Prisant LM, Carr AA: Antihypertensive drug therapy and insulin resistance. Am J Hypertens 1992, 5:775\u2013777.","journal-title":"Am J Hypertens"},{"key":"24_CR10","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1001\/archinte.151.7.1350","volume":"151","author":"JH Warram","year":"1991","unstructured":"Warram JH, Laffel LM, Valsania P, et al.: Excess mortality associated with diuretic therapy in diabetes mellitus. Arch Intern Med 1991, 151:1350\u20131356.","journal-title":"Arch Intern Med"},{"key":"24_CR11","doi-asserted-by":"crossref","first-page":"71S","DOI":"10.1016\/S0002-9343(96)00270-7","volume":"101","author":"JM Neutel","year":"1996","unstructured":"Neutel JM: Metabolic manifestations of low-dose diuretics. Am J Med 1996, 101:71S-82S.","journal-title":"Am J Med"},{"key":"24_CR12","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1001\/jama.276.23.1886","volume":"276","author":"JD Curb","year":"1996","unstructured":"Curb JD, Pressel SL, Cutler JA, et al.: Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA 1996, 276:1886\u20131892. Compared with placebo, low-dose diuretics reduced fatal and nonfatal myocardial infarctions but not fatal and nonfatal strokes.","journal-title":"JAMA"},{"key":"24_CR13","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0140-6736(98)05012-0","volume":"353","author":"L Hansson","year":"1999","unstructured":"Hansson L, Lindholm LH, Niskanen L, et al.: Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999, 353:611\u2013616. Captopril (and diuretics) compared with diuretics and b-blockers decreased fatal and nonfatal myocardial infarctions but not fatal and nonfatal strokes.","journal-title":"Lancet"},{"key":"24_CR14","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/bmj.317.7160.713","volume":"317","author":"United Kingdom Prospective Diabetes Study Group","year":"1998","unstructured":"United Kingdom Prospective Diabetes Study Group: Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998, 317:713\u2013720.","journal-title":"BMJ"},{"key":"24_CR15","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1136\/bmj.317.7160.703","volume":"317","author":"United Kingdom Prospective Diabetes Study Group","year":"1998","unstructured":"United Kingdom Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998, 317:703\u2013713.","journal-title":"BMJ"},{"key":"24_CR16","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1001\/jama.276.10.785","volume":"276","author":"NO Borhani","year":"1996","unstructured":"Borhani NO, Mercuri M, Borhani PA, et al.: Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial. JAMA 1996, 276:785\u2013791.","journal-title":"JAMA"},{"key":"24_CR17","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(05)70455-4","volume":"350","author":"RP Byington","year":"1997","unstructured":"Byington RP, Craven TE, Furberg CD, Pahor M: Isradipine, raised glycosylated haemoglobin, and risk of cardiovascular events. Lancet 1997, 350:1075\u20131076.","journal-title":"Lancet"},{"key":"24_CR18","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJM199803053381003","volume":"338","author":"RO Estacio","year":"1998","unstructured":"Estacio RO, Jeffers BW, Hiatt WR, et al.: The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998, 338:645\u2013652. Fewer myocardial infarctions were seen with enalapril than with nisoldipine.","journal-title":"N Engl J Med"},{"key":"24_CR19","doi-asserted-by":"crossref","first-page":"9R","DOI":"10.1016\/S0002-9149(98)00750-4","volume":"82","author":"RO Estacio","year":"1998","unstructured":"Estacio RO, Schrier RW: Antihypertensive therapy in type 2 diabetes: implications of the Appropriate Blood Pressure Control in Diabetes (ABCD) trial. Am J Cardiol 1998, 82:9R-14R.","journal-title":"Am J Cardiol"},{"key":"24_CR20","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2337\/diacare.21.4.597","volume":"21","author":"P Tatti","year":"1998","unstructured":"Tatti P, Pahor M, Byington RP, et al.: Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998, 21:597\u2013603.","journal-title":"Diabetes Care"},{"key":"24_CR21","doi-asserted-by":"crossref","first-page":"655","DOI":"10.2337\/diacare.21.4.655","volume":"21","author":"RM Califf","year":"1998","unstructured":"Califf RM, Granger CB: Hypertension and diabetes and the Fosinopril versus Amlodipine Cardiovascular Events Trial (FACET). More ammunition against surrogate end points. Diabetes Care 1998, 21:655\u2013657.","journal-title":"Diabetes Care"},{"key":"24_CR22","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","volume":"351","author":"L Hansson","year":"1998","unstructured":"Hansson L, Zanchetti A, Carruthers SG, et al.: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998, 351:1755\u20131762. Intense blood pressure control with felodipine, enalapril, and hydrochlorothiazide reduced overall cardiovascular events and mortality but not myocardial infarction and strokes.","journal-title":"Lancet"},{"key":"24_CR23","doi-asserted-by":"crossref","first-page":"20R","DOI":"10.1016\/S0002-9149(98)00752-8","volume":"82","author":"JA Staessen","year":"1998","unstructured":"Staessen JA, Thijs L, Gasowski J, et al.: Treatment of isolated systolic hypertension in the elderly: further evidence from the systolic hypertension in Europe (Syst-Eur) trial. Am J Cardiol 1998, 82:20R-22R.","journal-title":"Am J Cardiol"},{"key":"24_CR24","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1056\/NEJM199903043400902","volume":"340","author":"J Tuomilehto","year":"1999","unstructured":"Tuomilehto J, Rastenyte D, Birkenhager WH, et al.: Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N Engl J Med 1999, 340:677\u2013684. Nitrendipine alone or in combination with enalapril and hydrochlorothiazide decreased fatal and nonfatal strokes and cardiovascular mortality but not myocardial infarctions.","journal-title":"N Engl J Med"},{"key":"24_CR25","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S0140-6736(05)78489-0","volume":"351","author":"M Pahor","year":"1998","unstructured":"Pahor M, Psaty BM, Furberg CD: Treatment of hypertensive patients with diabetes. Lancet 1998, 351:689\u2013690.","journal-title":"Lancet"},{"key":"24_CR26","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1056\/NEJM199803053381009","volume":"338","author":"JA Cutler","year":"1998","unstructured":"Cutler JA: Calcium-channel blockers for hypertension\u2014uncertainty continues. N Engl J Med 1998, 338:679\u2013681.","journal-title":"N Engl J Med"},{"key":"24_CR27","doi-asserted-by":"crossref","first-page":"40R","DOI":"10.1016\/S0002-9149(98)00757-7","volume":"82","author":"NR Poulter","year":"1998","unstructured":"Poulter NR: Calcium antagonists and the diabetic patient: a response to recent controversies. Am J Cardiol 1998, 82:40R-41R.","journal-title":"Am J Cardiol"},{"key":"24_CR28","doi-asserted-by":"crossref","first-page":"42R","DOI":"10.1016\/S0002-9149(98)00758-9","volume":"82","author":"HH Parving","year":"1998","unstructured":"Parving HH: Calcium antagonists and cardiovascular risk in diabetes. Am J Cardiol 1998, 82:42R-44R.","journal-title":"Am J Cardiol"},{"key":"24_CR29","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(97)05381-6","volume":"350","author":"JA Staessen","year":"1997","unstructured":"Staessen JA, Fagard R, Thijs L, et al.: Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997, 350:757\u2013764.","journal-title":"Lancet"},{"key":"24_CR30","first-page":"141A","volume":"12","author":"RW Schrier","year":"Hypertens1999","unstructured":"Schrier RW, Estacio RO, Jeffers BW, et al. ABCD-2V: Appropriate Blood pressure Control in Diabetes-part 2 with Valsartan. Am J Hypertens1999, 12(part2):141A.","journal-title":"Am J"},{"key":"24_CR31","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/0895-7061(96)00037-4","volume":"9","author":"BR Davis","year":"1996","unstructured":"Davis BR, Cutler JA, Gordon DJ, et al.: Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group. Am J Hypertens 1996, 9(4 pt 1):342\u2013360. This trial has the potential to show whether one drug is superior to another in the treatment of diabetic hypertensive patients.","journal-title":"Am J Hypertens"}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-996-0024-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11906-996-0024-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-996-0024-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T01:09:51Z","timestamp":1683853791000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11906-996-0024-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,12]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1999,12]]}},"alternative-id":["24"],"URL":"https:\/\/doi.org\/10.1007\/s11906-996-0024-9","relation":{},"ISSN":["1522-6417","1534-3111"],"issn-type":[{"value":"1522-6417","type":"print"},{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,12]]}}}